SAN DIEGO, March 11 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced 2009 fourth quarter and full year financial results and accomplishments.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

Optimer reported a net loss for the three months ended December 31, 2009 of $9.6 million, or $0.28 per common share, as compared to a net loss of $10.4 million, or $0.35 per common share, for the same period in 2008.  Optimer reported a net loss for the year ended December 31, 2009 of $42.2 million, or $1.30 per common share, as compared to a net loss of $35.6 million, or $1.24 per common share, for 2008. The increase of $6.6 million was due primarily to an increase in development expenses, manufacturing scale-up expenses, and expenses to prepare regulatory filings related to fidaxomicin and Pruvel™ (prulifloxacin).

As of December 31, 2009, Optimer held cash, cash equivalents and short-term investments of $38.2 million.  In March 2010, Optimer raised an additional $51.2 million of net proceeds in a public offering of common stock.

"Recently, we announced robust results from our second Phase 3 trial of fidaxomicin confirming the positive results of our first Phase 3 trial showing that fidaxomicin has the potential to be a first-in-class drug for the treatment of Clostridium difficile infection," said Michael N. Chang, President and CEO of Optimer. "2010 will be a significant year for Optimer, as we focus on completing fidaxomicin and Pruvel regulatory filings, publish existing data and continue to prepare for the commercialization of these product candidates."

Optimer expects to use cash, cash equivalents and short-term investments of approximately $50 million for its operating activities in 2010, based on its current operating plans.

Optimer 2009 and Recent Highlights

• Announced positive results from the second Phase 3 trial of fidaxomicin in Clostridium difficile infection (CDI) confirming the results of our first Phase 3 trial. 91.7% of patients treated with fidaxomicin (per protocol population) achieved clinical cure vs. 90.6% for Vancocin®.  Importantly, fidaxomicin also showed significantly lower recurrence rates (p=0.002) and higher global cure rates (p<0.001) compared to Vancocin.  As in the first Phase 3 trial, fidaxomicin was well-tolerated in the study. Additional data from this trial will be presented at medical and scientific conferences this year.
• Raised $51.2 million in net proceeds in a public offering of common stock in March 2010.  Also raised $32.9 million in gross proceeds in a registered direct offering in March 2009.
• Abstracts related to Optimer's first Phase 3 study of fidaxomicin highlighted fidaxomicin's unique profile as the first in a new antibiotic class with beneficial characteristics compared to vancomycin for treating CDI such as lower recurrence rates, reduced risk of vancomycin-resistant enteroccoci (VRE) acquisition, faster time to resolution of diarrhea, and improved outcomes for patients also receiving concomitant antibiotics.  In addition, data presented on fidaxomicin showed a favorable pharmacokinetic profile, and a safety profile comparable to that of vancomycin.  The data was presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in September 2009 and at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in October 2009.
• Top-line data from Optimer's first Phase 3 study of fidaxomicin showed the trial met its primary endpoint of achieving clinical cure compared to Vancocin® , that patients treated with fidaxomicin experienced a reduction in CDI recurrence compared to Vancocin (p=0.004) and had a higher global cure compared to Vancocin (p=0.006). In addition, data was presented on CDI patient risk factors believed to be predictive of negative treatment outcomes.  These risk factors include albumin levels, white blood cell (WBC) count and temperature and strain types of CDI. Overall, the data showed that fidaxomicin demonstrated a lower recurrence rate compared to Vancocin (p=0.004) regardless of albumin levels, WBC count and temperature, as well as for patients with non-BI (NAP1/027) strains.  This data was presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting in May 2009 and at the Digestive Disease Week (DDW) conference in June 2009.
• Production patent for fidaxomicin issued by the United States Patent and Trademark Office.
• Announced positive results from the second Phase 3 trial of Pruvel for the treatment of infectious diarrhea.  The results were presented by primary investigator Robert Steffen, M.D., at ICAAC in September 2009. The trial achieved the primary endpoint of median Time to Last Unformed Stool (TLUS). Median TLUS for patients treated with Pruvel was 32.8 hours, which was a statistically significant improvement from the TLUS for placebo (p< 0.0001). Pruvel was generally well tolerated and had a similar safety profile compared to placebo.
• Appointed industry veterans Robert L. Zerbe, M.D., President and Chief Executive Officer at QuatRx Pharmaceuticals Company and Peter E. Grebow, Ph.D., Executive Vice President of Worldwide Technical Operations at Cephalon, Inc., to Optimer's Board of Directors.
• Entered into a number of transactions involving OBI, Optimer's Taiwan subsidiary, to provide OBI with funding for the development of two of Optimer's early-stage, non-core programs, OPT-88 and OPT-822/821, and to allow Optimer to focus on fidaxomicin and Pruvel.
• The United States Patent and Trademark Office issued a patent which covers the composition of matter of CEM-101/(OP-1068), a macrolide derivative originally developed by Optimer and licensed to Cempra Pharmaceuticals, which recently completed a Phase 1 clinical trial for the treatment of respiratory infections.

Scheduled Conference Call

The Company will host both a conference call and webcast to discuss the fourth quarter and full year 2009 financial results and to provide a corporate update today, Thursday, March 11, 2010 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).

The conference call may be accessed by dialing (877) 375-5161 for domestic callers and (631) 291-4558 for international callers.  Please specify to the operator that you would like to join the "Optimer Earnings Call." The conference call will be webcast live under the Investors section of Optimer's website at www.optimerpharma.com, where it will be archived for 30 days following the call.    

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infectives to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is the first of a new class of antibiotics with narrow spectrum bactericidal activity targeted at the site of infection. Recently reported positive top-line results from the second Phase 3 trial confirmed the results from the first Phase 3 trial regarding fidaxomicin's safety and efficacy in patients with Clostridium difficile infection. Optimer has also successfully completed two Phase 3 trials with Pruvel™, for the treatment of travelers' diarrhea, a form of infectious diarrhea.  Additional information can be found at http://www.optimerpharma.com.

Forward-looking Statements

Statements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation all statements related to the development of fidaxomicin and Pruvel, anticipated uses of cash, cash equivalents and short term investments, the timing of anticipated regulatory submissions, and the future presentation of clinical data. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "goal" and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer's business including, without limitation, risks relating to: the timing, progress and likelihood of success of its product research and development programs, the timing and status of its preclinical and clinical development of potential drugs, uncertainty regarding regulatory requirements for approval and the timing of regulatory submissions, an inability to enter into partnerships on favorable terms or at all, and other risks detailed in Optimer's filings with the Securities and Exchange Commission.

    
    
                          Optimer Pharmaceuticals, Inc.                      
                      Consolidated Statements of Operations                  
    
                            Three Months Ended              Year Ended         
                               December 31,                December 31,        
                               ------------                ------------
                            2009          2008          2009          2008 
                            ----          ----          ----          ---- 
    Revenues:                                                                
      Research grants     $208,652      $128,695      $792,644      $973,370 
      Collaborative                                                          
       research                                                              
       agreements                -             -       100,000        50,000 
                               ---           ---       -------        ------ 
        Total revenues     208,652       128,695       892,644     1,023,370 
    Operating expenses:                                                      
      Research and                                                           
       development       7,195,983     8,032,064    33,715,430    29,035,828 
      Marketing            572,101       755,791     1,751,313     2,451,191 
      General and                                                            
       administrative    2,074,192     1,879,459     8,024,138     6,682,881 
                         ---------     ---------     ---------     --------- 
        Total                                                                
         operating                                                           
         expenses        9,842,276    10,667,314    43,490,881    38,169,900 
                         ---------    ----------    ----------    ---------- 
    Loss from                                                                
     operations         (9,633,624)  (10,538,619)  (42,598,237)  (37,146,530)
    Interest income                                                          
     and other, net         55,025       135,548       363,998     1,561,934 
                            ------       -------       -------     --------- 
    Net loss                                                                 
     allocable to                                                            
     common                                                                  
     stockholders       (9,578,599)  (10,403,071)  (42,234,239)  (35,584,596)
    Net loss
     attributable to
     noncontrolling
     interest,                        
     net of tax            141,682             -       141,682             - 
                           -------           ---       -------           --- 
    Net loss attributable
     to Optimer
     Pharmaceuticals,                       
     Inc. common                                                          
     stockholders      $(9,436,917) $(10,403,071) $(42,092,557) $(35,584,596)
                       ===========  ============  ============  ============ 
                                                                             
    Basic and diluted                                                        
     net loss per                                                            
     share                                                                   
     attributable to                                                         
     common                                                                  
     stockholders           $(0.28)       $(0.35)       $(1.30)       $(1.24)
                            ======        ======        ======        ====== 
    Shares used to compute
     basic and diluted net                             
     loss per share                                                         
     attributable to                                                       
     common                                                                
     stockholders       33,117,095    29,697,503    32,468,702    28,682,542 
                        ==========    ==========    ==========    ========== 
    
    
    
                           Optimer Pharmaceuticals, Inc.  
                            Consolidated Balance Sheets
                                                                             
                                    Year Ended                 
                                   December 31,                
                                   ------------                
                                2009          2008          
                                ----          ----          
          ASSETS                                          
    Current assets:                                       
        Cash and cash                                     
         equivalents       $17,054,328   $16,778,880          
        Short-term                                        
         investments        21,131,145    22,547,515          
        Prepaid expenses                                   
         and other current                                 
         assets                416,859       744,670          
                               -------       -------          
    Total current assets    38,602,332    40,071,065      
    Property and                                          
     equipment, net            672,896       694,183      
    Long-term investments      882,000     1,032,000      
    Other assets               498,762       498,250      
                               -------       -------      
    Total assets           $40,655,990   $42,295,498      
                           ===========   ===========      
                                                          
      LIABILITIES  AND STOCKHOLDERS'  EQUITY            
    
    Current liabilities:                                  
      Accounts payable      $2,625,240    $3,767,831          
      Accrued expenses       5,025,669     4,045,660          
                             ---------     ---------          
    Total current                                             
     liabilities            $7,650,909    $7,813,491          
    Deferred rent              253,474       251,504          
    Commitments and                                           
     contingencies                   -             -          
    Stockholders’ equity    32,751,607    34,230,503          
                            ----------    ----------          
    Total liabilities                                         
     and stockholders’                                        
     equity                $40,655,990   $42,295,498          
                           ===========   ===========          
        
        

SOURCE Optimer Pharmaceuticals, Inc.